Additional immune checkpoint targets, cytokine tethered TIL, as well as transient and stable gene insertion and inactivation are being developed. Also, PD-1+ selected TIL (in a trial), CD39/69 double negative TIL [1], Gen 3 (16 day) manufacturing (in a trial), core biopsy (in a trial) [2] and an IL-2 analog.